- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapeutic approaches in chondrosarcoma
Authors
Keywords
-
Journal
Future Oncology
Volume 13, Issue 7, Pages 637-648
Publisher
Future Medicine Ltd
Online
2017-01-30
DOI
10.2217/fon-2016-0226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
- (2015) Scott M. Schuetze et al. CANCER
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
- (2015) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis
- (2015) Huey-En Tzeng et al. CLINICAL SCIENCE
- Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study
- (2015) Anna Maria Frezza et al. EUROPEAN JOURNAL OF CANCER
- Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells
- (2015) Gemma Di Pompo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
- (2015) Luyuan Li et al. PLoS One
- Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
- (2015) Johnny Suijker et al. Oncotarget
- CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells
- (2015) Guan-Ting Liu et al. Oncotarget
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance
- (2014) Alberto S. Pappo et al. CANCER
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
- (2014) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
- (2014) V. T. Campbell et al. MOLECULAR CANCER THERAPEUTICS
- Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells
- (2014) Y Sun et al. Cell Death & Disease
- Genetic alterations in chondrosarcomas – keys to targeted therapies?
- (2014) Andre M. Samuel et al. CELLULAR ONCOLOGY
- GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study
- (2013) A. Italiano et al. ANNALS OF ONCOLOGY
- Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
- (2013) J G van Oosterwijk et al. BRITISH JOURNAL OF CANCER
- SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
- (2013) S. Michels et al. CANCER RESEARCH
- Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy
- (2013) Y.-X. Zhang et al. CLINICAL CANCER RESEARCH
- An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
- (2013) P. Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Induction of sarcomas by mutant IDH2
- (2013) C. Lu et al. GENES & DEVELOPMENT
- Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
- (2013) Jolieke G. van Oosterwijk et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma
- (2013) K.A. Thornton et al. INTERNATIONAL JOURNAL OF CANCER
- Survival analysis of patients with chondrosarcomas of the pelvis
- (2013) Andreas F. Mavrogenis et al. JOURNAL OF SURGICAL ONCOLOGY
- CXCR4-Targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis
- (2013) X. Sun et al. MOLECULAR CANCER THERAPEUTICS
- Increased Oxidative Metabolism in the Li–Fraumeni Syndrome
- (2013) Ping-Yuan Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
- (2012) Frank G. Schaap et al. ADVANCES IN ANATOMIC PATHOLOGY
- Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
- (2012) Rinat Bernstein-Molho et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma
- (2012) A. L. Ho et al. CANCER RESEARCH
- Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors
- (2012) Y. Bai et al. CANCER RESEARCH
- Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
- (2012) A. Naing et al. CLINICAL CANCER RESEARCH
- Pazopanib in the treatment of soft tissue sarcoma
- (2012) Patrick Schöffski Expert Review of Anticancer Therapy
- Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma
- (2012) Danielle Meijer et al. GENES CHROMOSOMES & CANCER
- Recent advances in the molecular understanding of glioblastoma
- (2012) Fonnet E. Bleeker et al. JOURNAL OF NEURO-ONCOLOGY
- Clinical outcome of central conventional chondrosarcoma
- (2012) Andrea Angelini et al. JOURNAL OF SURGICAL ONCOLOGY
- Deregulated MYC expression induces dependence upon AMPK-related kinase 5
- (2012) Lidan Liu et al. NATURE
- Cancer prevention by targeting angiogenesis
- (2012) Adriana Albini et al. Nature Reviews Clinical Oncology
- Expandable Prostheses for the Leg in Children
- (2012) Andreas F. Mavrogenis et al. ORTHOPEDICS
- Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model
- (2012) Jennifer Perez et al. PLoS One
- Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model
- (2012) M. J. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- INI1-Deficient Tumors
- (2011) Travis J. Hollmann et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance
- (2011) J. G. van Oosterwijk et al. ANNALS OF ONCOLOGY
- A Systematic Review and Meta-analysis of Intralesional Versus Wide Resection for Intramedullary Grade I Chondrosarcoma of the Extremities
- (2011) Michael Hickey et al. ANNALS OF SURGICAL ONCOLOGY
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
- (2011) M Fernanda Amary et al. NATURE GENETICS
- Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
- (2011) Twinkal C Pansuriya et al. NATURE GENETICS
- A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β
- (2010) Giovanni Grignani et al. CANCER
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
- (2010) R. Quek et al. CLINICAL CANCER RESEARCH
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
- (2010) Samuel Seoane et al. JNCI-Journal of the National Cancer Institute
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
- (2010) E F Dunn et al. ONCOGENE
- Targeting a Common Collaborator in Cancer Development
- (2010) A. P. Myers et al. Science Translational Medicine
- Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment
- (2009) Y. M. Schrage et al. CANCER RESEARCH
- Extended Intralesional Treatment versus Resection of Low-grade Chondrosarcomas
- (2009) Chad Aarons et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- COX-2 expression in chondrosarcoma: A role for celecoxib treatment?
- (2009) Y.M. Schrage et al. EUROPEAN JOURNAL OF CANCER
- The Role of Src in Solid Tumors
- (2009) D. L. Wheeler et al. ONCOLOGIST
- Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
- (2008) C Adams et al. CELL DEATH AND DIFFERENTIATION
- Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
- (2008) H. Jin et al. CLINICAL CANCER RESEARCH
- Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma
- (2008) P. Koppikar et al. CLINICAL CANCER RESEARCH
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started